Allied Corp Successfully Ships Second Commercial Cannabis Flower Export From Colombia to International Market
KELOWNA, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
KELOWNA, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two...
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the...
Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and...
Four new members enhance independence and diversity of Board of DirectorsAlvotech (NASDAQ and First North Growth Market: ALVO), a global...
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million...
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland,...
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals...
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths...
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
By Rohit Vashisht Competition in the pharmaceutical industry is driving a race to collect the most data and build the...
By Jonathan Wilkins Errors in the pharmaceutical supply chain can lead to late delivery, increased costs and poor-quality products, which...